ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
288.2 USD -1.23% Intraday chart for ICON Public Limited Company -5.81% +1.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Icon CFO Brennan to Depart for Outside Opportunity DJ
Icon Says CFO Brennan Leaving in Q4, Reaffirms Guidance MT
Brendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024 CI
Icon plc Reaffirm Earnings Guidance for the Year 2024 CI
Transcript : ICON Public Limited Company Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM
Transcript : ICON Public Limited Company Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM
Evercore ISI Adjusts Price Target on ICON to $350 From $325, Keeps Outperform Rating MT
UBS Adjusts ICON Price Target to $368 From $295, Maintains Buy Rating MT
Mizuho Securities Ups Price Target on ICON to $346 From $315, Keeps Buy Rating MT
Barclays Adjusts Price Target on ICON to $355 From $325, Maintains Overweight Rating MT
Truist Securities Raises Price Target on ICON to $367 From $357, Maintains Buy Rating MT
ICON Shares Rise After Q4 Results, Guidance Reaffirmed MT
Deutsche Bank Raises ICON Price Target to $345 From $320, Maintains Buy Rating MT
ICON Seeks M&A CI
Transcript : ICON Public Limited Company, Q4 2023 Earnings Call, Feb 22, 2024
ICON Q4 Adjusted Earnings, Revenue Increase; 2024 Guidance Affirmed MT
ICON Public Limited Company announces an Equity Buyback for $500 million worth of its shares. CI
Earnings Flash (ICLR) ICON Posts Q4 Revenue $2.07B, vs. Street Est of $2.09B MT
Earnings Flash (ICLR) ICON Reports Q4 EPS $3.46, vs. Street Est of $3.45 MT
ICON Public Limited Company Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
ICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024 CI
ICON Public Limited Company Reports Earnings Results for the Full Year Ended December 31, 2023 CI
The fate of the market depends on this Our Logo
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... Our Logo
ICON Public Limited Company authorizes a Buyback Plan. CI
Chart ICON Public Limited Company
More charts
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
288.2 USD
Average target price
352.8 USD
Spread / Average Target
+22.40%
Consensus
  1. Stock Market
  2. Equities
  3. ICLR Stock
  4. News ICON Public Limited Company
  5. ICON Public : Posts Higher Q2 Results from Year Ago, Updates Guidance -- Stock Down 3% After-Hours